1. Scrip
  2. >>Therapy Areas

ICAAC 2015: Scrip Connects With Cidara, MerLion And Paratek

 
• By Mandy Jackson

Scrip caught up with several biopharma executives on Sept. 18 during the Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC) and International Congress of Chemotherapy and Infection (ICC) in San Diego to discuss the status of their anti-infective drug development programs.

Scrip caught up with several biopharma executives on Sept. 18 during the Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC) and International Congress of Chemotherapy and Infection (ICC) in San Diego to discuss the status of their anti-infective drug development programs.

For instance, Cidara Therapeutics Inc. will report its first human data for the antifungal CD101 this year; MerLion Pharmaceuticals GmbH is seeking Phase III funding or a partner for its antibiotic finafloxacin after a successful Phase II clinical trial; and Paratek Pharmaceuticals Inc. anticipates its first set of Phase III results for omadacycline by mid-2016

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Dermatological

More from Therapy Areas

Sustainability Key To ABL Bio’s Journey From ‘Good To Great’

 
• By Jung Won Shin

Helped by a recent major platform deal with GSK, South Korea's ABL Bio is aiming to build its R&D portfolio with an eye on being acquired in the future. CEO Sang Hoon Lee sat down with Scrip to explain the venture's journey so far and its ambitious roadmap.

Lilly Builds Obesity Momentum With New SURMOUNT Data Besting Novo Nordisk

 
• By Alaric DeArment

The presentation and publication of the Phase IIIb study showing greater efficacy for Zepbound over Wegovy come at a time when competition has been heating up between the two obesity medications.

Chinese Vaccine Makers Turn To Emerging Markets

 
• By Dexter Jie Yan

Chinese producers of novel vaccines are increasingly pivoting to developing markets overseas in the face of a collapse in their domestic sales.